Korean College of Rheumatology Biologics and Targeted Therapy Registry — KOBIO  

Rheumatoid Arthritis Clinical Trial

Official title: Korean College of Rheumatology Biologics and Targeted Therapy Registry

Status Recruiting

Clinical Trial Summary

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

Clinical Trial Description

This registry is a multi-center, prospective, observational program that will gather and analyze data on patients being treated with biologics and targeted synthetic DMARDs in Korea. In contrast to a controlled clinical trial, there is no imposed experimental intervention and solely the patients' physicians will determine the patient's treatment. Thus, the data captured and reported in this registry will reflect a "real world" approach to the treatment with biologics or targeted synthetic DMARDs. There will be no additional visit or laboratory test done outside the routine clinical practice. The selection of the agent, dosing, and treatment duration is determined by the investigator. Informed consent will be obtained from the patient prior to the collection of any data. ;

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Spondylitis
• Spondylitis, Ankylosing

• NCT number: NCT01965132
• Study type: Observational [Patient Registry]
• Source: Seoul National University Hospital
• Contact: Kichul Shin, MD
• Email: kideb1@snu.ac.kr
• Status: Recruiting
• Start date: December 1, 2012
• Completion date: June 30, 2030